Fig. 2From: A pan-cancer analysis of Dyskeratosis congenita 1 (DKC1) as a prognostic biomarkerAnalysis of DKC1 expression and survival prognosis in different tumors based on TCGA. A The overall survival analysis of DKC1 in 33 cancers. B The overall survival analysis in KIRP, NHSC, LGG, LIHC, MESO, READ, SARC and STAD. C The disease-free survival analysis of DKC1 in different cancers. D The disease-free survival analysis in LIHC, KIRP and UNMBack to article page